The in vivo inhibitory fucntion of the MHC-I a3 domain/CD8a interaction 2329318

L Linghua Zheng (The Ohio State University Comprehensive Cancer Center, College of Medicine) J Juanjuan Zhao Y Yang Xu L Lawrence Feng (ohio state university) J Jun Wang K Kareem Alsbei (ohio state university) T Tiffany Zhou (ohio state university) Q Qipeng Zhan (The Ohio State University Comprehensive Cancer Center, College of Medicine) X Xue Han (State Key Laboratory of Advanced Chemical Power Sources, Frontiers Science Center for New Organic Matter, Key Laboratory of Advanced Energy Materials Chemistry (Ministry of Education), Academy for Advanced Interdisciplinary Studies, College of Chemistry)

Abstract

Abstract Introduction Since the discovery of the MHC-I α3 domain/CD8α interaction approximately 40 years ago, numerous in vitro studies have demonstrated that this binding stabilizes the MHC-I/TCR complex and facilitates signaling for low-affinity or CD8-dependent TCRs. However, the in vivo significance of this interaction has remained largely unexplored. In this abstract, we present our recent findings regarding the in vivo blockade of the MHC-I α3 domain/CD8α interaction in both the absence and presence of antigen exposure. Methods We employed monoclonal antibodies directed against the α3 domain of MHC class I to selectively disrupt the interaction between the MHC-I α3 domain and CD8α. Specifically, two monoclonal antibodies targeting the α3 domains of H-2Kb and H-2Db were used in C57BL/6 mice. In addition, three monoclonal antibodies specific for the α3 domains of H-2Ld, H-2Dd, and H-2Kd were utilized in the BALB/c mice. These α3 domain—specific antibodies enable precise interrogation of MHC-I α3 domain—CD8α interactions under both antigen-dependent and antigen-independent conditions. Results Our results demonstrate that selective blockade of individual MHC-I α3 domain—CD8α interactions is sufficient to activate CD8+ T cells in the absence of antigen exposure. In the presence of antigen, blockade of either the H-2Db or H-2Kb α3 domain—CD8α interaction enhances ovalbumin peptide—induced, H-2Kb—restricted OT-I CD8+ T cell responses and prevents the development of CD8+ T cell tolerance. Importantly, blockade of either the H-2Db or H-2Kb α3 domain—CD8α interaction also reverses established H-2Kb—restricted OT-I CD8+ T cell tolerance. Conclusion These data suggest that the MHC-I α3 domain—CD8α interaction delivers an inhibitory signal to CD8+ T cells in vivo during antigen-independent homeostasis. In the presence of antigen, this interaction also plays an inhibitory role in vivo at multiple stages of CD8+ T cell activation. Funding Source Elsa Pardee Foundation, OSU startup. Topic Categories Immune Response Regulation: Molecular Mechanisms (IRM)

Article Details

Volume / Issue Vol. 215, Issue Supplement_1
Published August 01, 2026
ISSN 0022-1767
Publisher American Association of Immunologists

Authors (9)

L

Linghua Zheng

The Ohio State University Comprehensive Cancer Center, College of Medicine

J

Juanjuan Zhao

Y

Yang Xu

L

Lawrence Feng

ohio state university

J

Jun Wang

K

Kareem Alsbei

ohio state university

T

Tiffany Zhou

ohio state university

Q

Qipeng Zhan

The Ohio State University Comprehensive Cancer Center, College of Medicine

X

Xue Han

State Key Laboratory of Advanced Chemical Power Sources, Frontiers Science Center for New Organic Matter, Key Laboratory of Advanced Energy Materials Chemistry (Ministry of Education), Academy for Advanced Interdisciplinary Studies, College of Chemistry